Literature DB >> 19740382

Impaired macrophage function following bacterial stimulation in chronic granulomatous disease.

Farooq Z Rahman1, Bu'Hussain Hayee, Ronnie Chee, Anthony W Segal, Andrew M Smith.   

Abstract

Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is critical for phagocyte anti-microbial activity and plays a major role in innate immunity. Defects in genes coding for components of the NADPH oxidase enzyme system are responsible for chronic granulomatous disease (CGD), a rare primary neutrophil immunodeficiency associated with recurrent, life-threatening bacterial and fungal infections. Microbial killing and digestion within the neutrophil phagosomal compartment are defective in these patients. NADPH oxidase activity is also crucial for optimal macrophage and dendritic cell function and has recently been implicated in both cross-presentation and T-cell priming. We present evidence of impaired macrophage function in CGD, with attenuated pro-inflammatory cytokine and increased interleukin-10 secretion following bacterial stimulation. These results highlight additional abnormalities in macrophage function associated with CGD and the importance of NADPH oxidase activity in immunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19740382      PMCID: PMC2767315          DOI: 10.1111/j.1365-2567.2009.03112.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis.

Authors:  K Tobiume; A Matsuzawa; T Takahashi; H Nishitoh; K Morita ; K Takeda; O Minowa; K Miyazono; T Noda; H Ichijo
Journal:  EMBO Rep       Date:  2001-03       Impact factor: 8.807

2.  Toll receptor-mediated regulation of NADPH oxidase in human dendritic cells.

Authors:  Marisa Vulcano; Stefano Dusi; Daniele Lissandrini; Raffaele Badolato; Paola Mazzi; Elena Riboldi; Elena Borroni; Angelica Calleri; Marta Donini; Alessandro Plebani; Luigi Notarangelo; Tiziana Musso; Silvano Sozzani
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

3.  Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD).

Authors:  Joanne R Brown; David Goldblatt; Joanna Buddle; Louise Morton; Adrian J Thrasher
Journal:  J Leukoc Biol       Date:  2003-05       Impact factor: 4.962

4.  Cytokine release in healthy donors and patients with chronic granulomatous disease upon stimulation with Aspergillus fumigatus.

Authors:  Adilia Warris; Mihai G Netea; Jacob E Wang; Peter Gaustad; Bart-Jan Kullberg; Paul E Verweij; Tore G Abrahamsen
Journal:  Scand J Infect Dis       Date:  2003

5.  Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4.

Authors:  Ruby F Fernandez-Boyanapalli; S Courtney Frasch; Kathleen McPhillips; R William Vandivier; Brian L Harry; David W H Riches; Peter M Henson; Donna L Bratton
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

Review 6.  Gene therapy for chronic granulomatous disease.

Authors:  Cecilia N Barese; W Scott Goebel; Mary C Dinauer
Journal:  Expert Opin Biol Ther       Date:  2004-09       Impact factor: 4.388

7.  Cryptic O2- -generating NADPH oxidase in dendritic cells.

Authors:  Sylvie Elsen; Jacques Doussière; Christian L Villiers; Mathias Faure; Rolande Berthier; Anne Papaioannou; Nathalie Grandvaux; Patrice N Marche; Pierre V Vignais
Journal:  J Cell Sci       Date:  2004-05-01       Impact factor: 5.285

Review 8.  Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.

Authors:  Reinhard A Seger; Tayfun Gungor; Bernd H Belohradsky; Stephane Blanche; Pierre Bordigoni; Paolo Di Bartolomeo; Terence Flood; Paul Landais; Susanna Müller; Hulya Ozsahin; Justen H Passwell; Fulvio Porta; Shimon Slavin; Nico Wulffraat; Felix Zintl; Arnon Nagler; Andrew Cant; Alain Fischer
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

Review 9.  Gene therapy for chronic granulomatous disease.

Authors:  W Scott Goebel; Mary C Dinauer
Journal:  Acta Haematol       Date:  2003       Impact factor: 2.195

Review 10.  Interferon-gamma in the management of chronic granulomatous disease.

Authors:  J I Gallin
Journal:  Rev Infect Dis       Date:  1991 Sep-Oct
View more
  12 in total

1.  Persistence of the bacterial pathogen Granulibacter bethesdensis in chronic granulomatous disease monocytes and macrophages lacking a functional NADPH oxidase.

Authors:  Jessica Chu; Helen H Song; Kol A Zarember; Teresa A Mills; John I Gallin
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

2.  Extracellular superoxide dismutase in macrophages augments bacterial killing by promoting phagocytosis.

Authors:  Michelle L Manni; Lauren P Tomai; Callie A Norris; L Michael Thomas; Eric E Kelley; Russell D Salter; James D Crapo; Ling-Yi L Chang; Simon C Watkins; Jon D Piganelli; Tim D Oury
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

3.  G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunction.

Authors:  Bu'hussain Hayee; Aristotelis Antonopoulos; Emma J Murphy; Farooq Z Rahman; Gavin Sewell; Bradley N Smith; Sara McCartney; Mark Furman; Georgina Hall; Stuart L Bloom; Stuart M Haslam; Howard R Morris; Kaan Boztug; Christoph Klein; Bryan Winchester; Edgar Pick; David C Linch; Rosemary E Gale; Andrew M Smith; Anne Dell; Anthony W Segal
Journal:  Glycobiology       Date:  2011-03-08       Impact factor: 4.313

4.  A phagocyte dilemma...

Authors:  Adrian J Thrasher; Anthony W Segal
Journal:  Nat Immunol       Date:  2011-03       Impact factor: 25.606

5.  High levels of Crohn's disease-associated anti-microbial antibodies are present and independent of colitis in chronic granulomatous disease.

Authors:  Joyce E Yu; Suk See De Ravin; Gulbu Uzel; Carol Landers; Stephan Targan; Harry L Malech; Steven M Holland; Wenqing Cao; Noam Harpaz; Lloyd Mayer; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2010-10-16       Impact factor: 3.969

Review 6.  NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Authors:  Becky A Diebold; Susan M E Smith; Yang Li; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

7.  Cutting Edge: NOX2 NADPH Oxidase Controls Infection by an Intracellular Bacterial Pathogen through Limiting the Type 1 IFN Response.

Authors:  Jorge David Rojas Márquez; Taoyingnan Li; Adam R R McCluggage; Joel M J Tan; Aleixo Muise; Darren E Higgins; John H Brumell
Journal:  J Immunol       Date:  2020-12-07       Impact factor: 5.422

8.  The role of the innate immune system in granulomatous disorders.

Authors:  Helen J Petersen; Andrew M Smith
Journal:  Front Immunol       Date:  2013-05-24       Impact factor: 7.561

9.  Lentiviral vectors containing mouse Csf1r control elements direct macrophage-restricted expression in multiple species of birds and mammals.

Authors:  Clare Pridans; Simon Lillico; Bruce Whitelaw; David A Hume
Journal:  Mol Ther Methods Clin Dev       Date:  2014-04-09       Impact factor: 6.698

10.  Diminished macrophage apoptosis and reactive oxygen species generation after phorbol ester stimulation in Crohn's disease.

Authors:  Christine D Palmer; Farooq Z Rahman; Gavin W Sewell; Afshan Ahmed; Margaret Ashcroft; Stuart L Bloom; Anthony W Segal; Andrew M Smith
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.